CTI BioPharma (CTIC) : Traders are bullish on CTI BioPharma (CTIC) as it has outperformed the S&P 500 by a wide margin of 10.44% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 11.5%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 12.06% in the last 1 week, and is up 10.29% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 9.01% and the 50-Day Moving Average is 9.92%.The 200 Day SMA reached 39.71%. CTI BioPharma Corp. has dropped 8.79% during the last 3-month period . Year-to-Date the stock performance stands at -68.11%.
CTI BioPharma (NASDAQ:CTIC): After opening at $0.3999, the stock dipped to an intraday low of $0.39 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $0.4 and the buying power remained strong till the end. The stock closed at $0.3922 for the day, a gain of 0.56% for the day session. The total traded volume was 535,230. The stocks close on the previous trading day was $0.39.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.